

**Supplements for: Bipolar symptoms and lithium treatment affect neural signatures of adaptation of risk-taking to past outcomes during reward-guided decision-making**

Jacqueline Scholl, Priyanka Panchal, Natalie Nelissen, Lauren Z Atkinson, Nils Kolling, Kate EA Saunders, John Geddes, Matthew FS Rushworth, Anna C Nobre, Paul J Harrison, Catherine J Harmer

	<i>t.β_mean</i>	<i>t.λ_mean</i>	<i>t.γ_mean</i>	<i>t.β_sd</i>	<i>t.λ_sd</i>	<i>t.γ_sd</i>	<i>f.β_mean</i>	<i>f.λ_mean</i>	<i>f.γ_mean</i>	<i>f.β_sd</i>	<i>f.λ_sd</i>	<i>f.γ_sd</i>
<i>t.β_mean</i>		0.005	0.031	0.059	0.014	0.055	0.854***	-0.141**	0.004	-0.186***	0.118*	0.011
<i>t.λ_mean</i>	0.005		0.035	0.020	0.071	0.012	-0.341***	0.961***	0.023	0.305***	0.517***	0.589***
<i>t.γ_mean</i>	0.031	0.035		-0.060	0.110*	0.034	0.033	0.048	0.904***	0.066	0.112*	0.037
<i>t.β_sd</i>	0.059	0.020	-0.060		-0.011	-0.014	0.038	0.025	-0.073	0.273***	0.076	-0.022
<i>t.λ_sd</i>	0.014	0.071	0.110*	-0.011		-0.001	0.041	0.091	0.094	0.178***	0.626***	-0.001
<i>t.γ_sd</i>	0.055	0.012	0.034	-0.014	-0.001		0.067	0.017	0.034	-0.025	-0.006	0.429***
<i>f.β_mean</i>	0.854***	-0.341***	0.033	0.038	0.041	0.067		-0.453***	0.014	-0.192***	-0.060	-0.215***
<i>f.λ_mean</i>	-0.141**	0.961***	0.048	0.025	0.091	0.017	-0.453***		0.038	0.373***	0.519***	0.594***
<i>f.γ_mean</i>	0.004	0.023	0.904***	-0.073	0.094	0.034	0.014	0.038		0.029	0.077	0.008
<i>f.β_sd</i>	-0.186***	0.305***	0.066	0.273***	0.178***	-0.025	-0.192***	0.373***	0.029		0.300***	0.225***
<i>f.λ_sd</i>	0.118*	0.517***	0.112*	0.076	0.626***	-0.006	-0.060	0.519***	0.077	0.300***		0.327***
<i>f.γ_sd</i>	0.011	0.589***	0.037	-0.022	-0.001	0.429***	-0.215***	0.594***	0.008	0.225***	0.327***	

*Computed correlation used pearson-method with listwise-deletion.*

**Table S1. Parameter recovery, at home.** Parametric (Pearson) correlations between ground-truth ('t.') and fitted ('f.') parameters. We simulated 400 participants with mean ('\_mean') and standard ('\_sd') from which choices for individual sessions of 20 trials were then generated (see supplementary methods [2A]). Simulated participants provided 47-50 sessions of data (50%-100% range of COMET study). Parameters: inverse temperature ( $\beta$ ), sensitivity to loss utility ( $\lambda$ ), change in loss sensitivity after prev. trial win vs. loss ( $\gamma$ ), choice repetition risky/safe compared to previous trial ( $\epsilon$ ). Results show that recovery for mean parameters was very good (correlations between true and corresponding fitted, all  $>0.68$ ). However, recovery for standard deviations was poor (e.g.  $\gamma\_sd$ :  $r=0.24$ ). Given this, we decided not to analyse group differences in standard deviations.

<b>A) Low MDQ, High MDQ, Bipolar disorder (BD) groups (baseline)</b>			
<b>Group</b>	<b>Choice consist. (<math>\beta</math>)</b>	<b>Loss sensitivity (<math>\lambda</math>)</b>	<b>Outcome history effect (<math>\gamma</math>)</b>
<b>3 group gradient</b>	-0.148 [-0.5547 0.2733]	<b>-0.274 [-0.4941 -0.0547]</b>	<b>-0.053 [-0.109 -1e-04]</b>
<b>High vs low MDQ</b>	-0.4 [-1.18 0.33]	-0.01 [-0.41 0.37]	-0.05 [-0.12 0.02]
<b>BD vs high MDQ</b>	0.13 [-0.62 0.91]	<b>-0.5 [-0.92 -0.1]</b>	-0.07 [-0.19 0.04]
<b>BD vs low MDQ</b>	-0.27 [-1.06 0.49]	<b>-0.51 [-0.95 -0.1]</b>	<b>-0.12 [-0.24 -0.01]</b>
<b>BD</b>	5.82 [5.22 6.46]	0.89 [0.57 1.24]	-0.01 [-0.11 0.09]
<b>High MDQ</b>	5.7 [5.11 6.23]	1.39 [1.11 1.68]	0.07 [0.01 0.12]
<b>Low MDQ</b>	6.1 [5.52 6.69]	1.41 [1.11 1.71]	0.11 [0.06 0.17]
<b>Day</b>	-0.554 [-0.763 -0.334]	-0.241 [-0.332 -0.152]	-0.03 [-0.062 0.002]
<b>B) BD groups, pre/post * lithium/placebo</b>			
<b>Group</b>	<b>Choice consist. (<math>\beta</math>)</b>	<b>Loss sensitivity (<math>\lambda</math>)</b>	<b>Outcome history effect (<math>\gamma</math>)</b>
<b>Lith/pla x pre/post</b>	0.194 [-0.9019 1.2494]	-0.005 [-0.4996 0.4852]	-0.108 [-0.2946 0.0818]
<b>Lith pre vs post</b>	0.37 [-0.48 1.16]	-0.17 [-0.52 0.15]	-0.06 [-0.19 0.07]
<b>Pla pre vs post</b>	0.17 [-0.75 1.1]	-0.16 [-0.55 0.19]	0.05 [-0.09 0.2]
<b>Lith vs pla (pre)</b>	0.76 [-0.41 1.85]	0.19 [-0.24 0.59]	-0.07 [-0.23 0.1]
<b>Lith vs pla (post)</b>	0.55 [-0.61 1.69]	0.2 [-0.22 0.62]	0.04 [-0.09 0.16]
<b>Lith (pre)</b>	6.35 [5.37 7.26]	1.09 [0.81 1.41]	-0.03 [-0.14 0.09]
<b>Placebo (pre)</b>	5.6 [4.59 6.61]	0.9 [0.58 1.2]	0.04 [-0.09 0.16]
<b>Lith (post)</b>	5.99 [5.15 6.83]	1.26 [0.97 1.54]	0.03 [-0.06 0.12]
<b>Placebo (post)</b>	5.44 [4.53 6.35]	1.06 [0.76 1.38]	-0.01 [-0.11 0.08]

**Table S2. Computational modelling results.** Computational model parameters for the longitudinal data. A) Comparison of the three groups (mood elevation gradient, ordered factors across low MDQ, high MDQ, patients with BD, at baseline). Values are means and 95% Bayesian Credible Intervals; for comparisons between groups, significance is defined as 95% intervals not including zero. All estimates were obtained from hierarchical regression models (Main text Methods, section ‘Model fitting’). The groups differed in their loss sensitivity (patients with BD being least sensitive to losses) and outcome history effects (patients with BD being least sensitive to past trial outcomes). How participants performed the task changed over time (effect of ‘Day’), in particular they became more random (lower inverse temperature) and less sensitive to potential losses (loss sensitivity). B) Comparison for the effect of lithium vs. placebo in hierarchical models (Main text Methods, section ‘Model fitting’, term of interest is the interaction drug (lithium/placebo) \* time (pre/post)). No significant group differences were found.

A) Low MDQ, High MDQ, Bipolar disorder (BD) groups (baseline)				
Group	Positive PANAS		Negative PANAS	
	Mean	Standard deviation	Mean	Standard deviation
3 group gradient	0.121 [-0.6861 0.9147]	<b>0.221 [0.111 0.334]</b>	<b>2.61 [1.9103 3.2709]</b>	<b>0.638 [0.451 0.832]</b>
High vs low MDQ	0.1 [-1.38 1.54]	<b>0.34 [0.14 0.55]</b>	<b>1.33 [0.03 2.58]</b>	<b>0.73 [0.41 1.07]</b>
BD vs high MDQ	0.05 [-1.27 1.3]	0.1 [-0.13 0.33]	<b>2.02 [0.86 3.27]</b>	<b>0.59 [0.23 0.97]</b>
BD vs low MDQ	0.16 [-1.08 1.48]	<b>0.45 [0.22 0.69]</b>	3.34 [2.11 4.54]	1.32 [0.95 1.69]
BD	6.81 [5.76 7.93]	1.16 [0.98 1.34]	4.93 [3.94 5.87]	1.12 [0.85 1.4]
High MDQ	6.77 [5.73 7.9]	1.05 [0.91 1.2]	2.89 [1.99 3.73]	0.54 [0.3 0.76]
Low MDQ	6.66 [5.59 7.71]	0.71 [0.56 0.86]	1.58 [0.67 2.57]	-0.2 [-0.43 0.05]
Day	-0.297 [-0.546 -0.053]	NA	-0.001 [-0.131 0.129]	NA
B) BD groups, pre/post * lithium/placebo				
Group	Positive PANAS		Negative PANAS	
	Mean	Standard deviation	Mean	Standard deviation
Lith/pla x pre/post	-0.276 [-1.6301 1.071]	0.019 [-0.4158 0.4525]	0.258 [-0.8633 1.3603]	-0.084 [-0.4952 0.3369]
Lith pre vs post	1.02 [-0.02 2.06]	0.22 [-0.07 0.51]	0.85 [-0.01 1.7]	0.1 [-0.18 0.38]
Pla pre vs post	1.29 [0.01 2.54]	0.2 [-0.12 0.5]	0.59 [-0.42 1.63]	0.19 [-0.11 0.49]
Lith vs pla (pre)	0.19 [-1.52 1.9]	0.06 [-0.42 0.54]	-0.33 [-2.01 1.29]	-0.2 [-0.66 0.24]
Lith vs pla (post)	0.47 [-1.67 2.43]	0.04 [-0.39 0.47]	-0.61 [-2.37 1.4]	-0.12 [-0.55 0.33]
Lith (pre)	7.89 [5.86 9.8]	1.17 [0.85 1.49]	6.32 [4.53 8.16]	0.88 [0.57 1.18]
Placebo (pre)	7.72 [5.68 9.73]	1.1 [0.76 1.44]	6.65 [4.86 8.57]	1.08 [0.74 1.39]
Lith (post)	6.87 [4.91 8.82]	0.95 [0.68 1.25]	5.47 [3.65 7.36]	0.78 [0.46 1.07]
Placebo (post)	6.41 [4.33 8.48]	0.91 [0.59 1.2]	6.07 [4.15 7.99]	0.89 [0.58 1.21]

**Table S3. Group difference for mood (PANAS) mean and standard deviations.** A) Comparison of the three groups (mood elevation gradient, ordered factors across low MDQ, high MDQ, patients with BD [pre treatment]). Values are means and 95% Bayesian Credible Intervals; significance is defined as 95% intervals not including zero. All estimates were obtained from hierarchical regression models (Main text Methods, section ‘Model fitting’). The groups differed in variability (standard deviation (log scale) for positive and negative PANAS with patients with BD showing the highest variability. Groups also differed in the mean values for negative PANAS. B) Comparison for the effect of lithium vs. placebo in hierarchical models (Main text Methods, section ‘Model fitting’, term of interest is the interaction drug (lithium/placebo) \* time (pre/post)). No significant group differences were found.

	Choice consist. ( $\beta$ )	Loss sensitivity ( $\lambda$ )	Choice history effect ( $\gamma$ )
<b>Bip Lith (post)</b>	8.8 [7.08 10.52]	1.48 [0.92 2.03]	-0.07 [-0.31 0.17]
<b>Bip Pla (post)</b>	6.58 [4.55 8.48]	1.58 [0.95 2.29]	-0.01 [-0.27 0.27]
<b>High MDQ</b>	7.06 [6.08 8.08]	1.76 [1.38 2.07]	0.13 [-0.02 0.27]
<b>Low MDQ</b>	7.34 [6.28 8.34]	1.73 [1.38 2.09]	0.12 [-0.03 0.25]
<b>4 Group diff (post)</b>	-0.002 [-0.74 0.67]	-0.059 [-0.278 0.157]	-0.051 [-0.141 0.039]
<b>Lith vs pla (post)</b>	2.23 [-0.3 4.95]	-0.1 [-0.96 0.75]	-0.06 [-0.42 0.28]
<b>High vs low MDQ</b>	-0.28 [-1.61 1.21]	0.03 [-0.46 0.53]	0.02 [-0.17 0.21]

**Table S4. FMRI session computational parameters.** Values are reported separately for each of the four groups (Bipolar participants on lithium ('Bip Lith'), bipolar participants on placebo ('Bip Pla'), healthy volunteers with low or high mood instability ('Low MDQ', 'High MDQ') as means and 95% Bayesian Credible Intervals (intervals not including zero are significant). All estimates were obtained from linear regression models allowing correcting for age and gender. Group differences were computed across all four groups ('4 group diff'). Group differences are also reported separately comparing high and low mood instability participants ('High vs. low MDQ') and lithium vs. placebo participants ('Lith vs pla'). There were no significant group differences.

	$\beta_{mean}$	$\lambda_{mean}$	$\gamma_{mean}$	$\beta_{fmri}$	$\lambda_{fmri}$	$\gamma_{fmri}$
$\beta_{mean}$		-0.043	0.147	0.394***	-0.249*	-0.067
$\lambda_{mean}$	-0.043		0.101	-0.180	0.426***	0.178
$\gamma_{mean}$	0.147	0.101		-0.047	-0.034	-0.058
$\beta_{fmri}$	0.394***	-0.180	-0.047		-0.525***	-0.076
$\lambda_{fmri}$	-0.249*	0.426***	-0.034	-0.525***		0.193
$\gamma_{fmri}$	-0.067	0.178	-0.058	-0.076	0.193	


*Computed correlation used pearson-method with listwise-deletion.*

**Table S5. Correlations between parameters from longitudinal and FMRI data.** For all but one parameter, computational parameters derived from longitudinal measurements and those obtained during the FMRI scan correlate significantly. Only for the outcome history effect parameter ( $\gamma$ ) are the correlations not significant. Correlations were computed using Pearson correlations across combined data from all four participant groups.


<b>Low and high MDQ groups combined</b>	x	y	z	max z-score	p-value (2-tailed)	# voxels
<b>Reward utility (chosen - unchosen) at choice</b>						
<i>Activation</i>						
Precuneus, primary motor area (M1), caudal cingulate zone (CCZ), supplementary motor area (SMA), posterior rostral cingulate zone (RCZp) [2]	-12	-44	50	4.22	2.08E-13	3106
Area 9/46 and 45a and 47m and 47o and IFS [2,3,4]	48	8	44	4.85	6.16E-13	2961
Temporal lobve (right)	60	-28	-2	4.47	4.86E-11	2401
Temporoparietal junction (TPJa) [1] (left)	-48	-44	18	3.93	2.90E-10	2184
Spanning precuneus and intracalcarine cortex	-18	-62	12	3.94	4.20E-09	1867
Area 47m and 47o (left) [2]	-40	42	-4	4.02	1.19E-07	1472
Superior parietal lobe (SPLA) [1] (left)	-32	-40	54	3.82	1.58E-04	812
Area 8a [3] (left)	-46	4	42	4.03	4.28E-04	728
Area 8m [2]	4	44	38	5.11	8.64E-03	493
<b>Loss utility (chosen - unchosen) at choice</b>						
<i>Activation</i>						
Rostral cingulate zone (RCZa) [2]	12	28	26	3.26	2.06E-02	431
<b>Last trial's win/loss magnitude (signed) at choice</b>						
<i>Activation</i>						
Ventral striatum (bilateral) and ventromedial prefrontal cortex (14m and 11m) and medial frontal pole (FPM) [2]	-18	12	-8	4.37	4.52E-13	3084
Occipital cortex	-16	-84	-2	3.7	1.72E-02	454
<b>Win/loss magnitude (signed) at outcome</b>						
<i>Activation</i>						
Ventral striatum and vmPFC (14m) [2]	14	12	-8	8.88	1.88E-30	9977
Inferior parietal lobe (IPLA) [1], left	-58	-18	26	4.65	2.80E-08	1708
Area 8m [2], left	-16	38	42	5	3.58E-07	1442
Primary motor area (M1) [2], right	20	-28	72	4.06	4.76E-07	1409
Occipital lobe, left	30	-88	-6	4.94	3.10E-06	1208
Precuneus, bilateral	-16	-52	12	4.58	9.78E-06	1093
Occipital lobe, right	-28	-92	4	4.72	2.56E-04	792
Temporal lobe, left	-56	-38	-12	4.09	3.22E-04	772
Inferior parietal lobe (IPLA, IPLD, IPLC) [1], left	-42	-66	40	5.47	8.48E-04	690
Cerebellum (right)	42	-70	-38	3.57	3.32E-02	408
<i>Deactivation</i>						
Pre supplementary motor area (pre-SMA) [2]	2	16	52	4.72	0.00033	770

**Table S6. General task brain (de)activations.** Data across the low and high mood instability (MDQ) groups was combined to identify general brain (de)activations during the task figure 3). Coordinates are reported in MNI space. Significance was determined using cluster-based thresholding (methods section “fMRI analysis – whole-brain”), with inclusion threshold:  $z=2.3$

and significance  $p < 0.05$  two-tailed. The maximum z-value of the cluster, the p-value and number of voxels are given for each cluster. Anatomical labels are based on: [1] (1), [2] (2), [3] (3), [4] (4), [5] (5).



**Figure S1. Mood (PANAS) variability (standard deviation).** A) Mood elevation gradient (ordered factor with low MDQ < high MDQ < patients with BD at baseline) is linked to increased variability (standard deviation) for both positive and negative mood (PANAS). B) In contrast, lithium (as interaction term drug (lithium/placebo) \* time (pre/post)) does not affect variability of mood. See table S3 for statistical values.



**Figure S2. FMRI designs.** Correlations of the haemodynamically convolved regressors for FMRI design 1 (A) and design 2 (B). No value regressors exceeded correlations of  $r > 0.5$  with any other regressors or confounds. Abbreviations: chosen reward utility (rewUtilC), unchosen reward utility (rewUtilUC), chosen loss utility (lossUtilC), last trial's outcome, i.e. points won or lost, e.g. +10 or -20 (LastWinLoMag), current trial's outcome (WinLossWithMag), relative reward utility (rewUtilCmUC), interaction between last trial's outcome and the current trial's loss utility (LastWinLoMagxLossUtilCmUC).

## Supplementary methods

### [1] Additional participant information

#### [1A] Exclusion criteria

##### Healthy volunteers with low and high mood instability:

Common inclusion criteria across both groups were: over 18 years old, no current medication (other than contraceptive pill), no use of antidepressants, antipsychotics, lithium or anticonvulsant medication in the last 6 weeks, no contraindication to MRI or MEG. Participants were recruited based on their scores of mood instability (MDQ [ref]). The questionnaire includes first questions describing symptoms of bipolar and second a question about whether the different symptoms occurred at the same time. Participants were included in the low MDQ group if their number of reported symptoms was 5 or less. Participants were included in the high MDQ group if they reported 7 or more symptoms and report that they have happened at the same time. Additionally, in the low mood instability group, we excluded participants with a current or past diagnosis of an axis 1 psychiatric disorder (assessed using DSM-IV interview) or a first degree relative with bipolar disorder. In the high mood instability group, we excluded participants with a current or past diagnosis of an axis 1 psychiatric disorder other than bipolar disorder I or II, major depression or anxiety disorders.

**Participants diagnosed with bipolar disorder:**

Inclusion criteria: over 18 years old, meeting criteria for BDI, BDII or BDNOS as assessed using the Structured Clinical Interview for DSM-V Axis I Disorders (SCID-I), clinically significant mood instability (established through interview), not currently suicidal (currently suicidal assessed as a score of  $\geq 4$  on the C-SSRS (Columbia Suicide Severity Rating Scale Score (6)), no counterindications to lithium (assessed through pre-treatment tests including renal, cardiac, thyroid and parathyroid functions), not currently taking any psychotropic drugs that could not be withdrawn, not requiring acute treatment so that placebo would be inappropriate, participation in a previous research trial in the past 12 weeks. Participants with counterindications to MRI scanner were included in the behavioural part of the study.

**[1B] Larger study – full information****Volunteers:**

The data presented here was part of larger study (CONBRIO, Collaborative Oxford Network for Bipolar Research to Improve Outcomes: The cognitive neuroscience of mood instability; Cognition and Mood Evolution across Time (COMET) – MSD-IDREC-C2-2014-023). Participants who expressed interested in the study were given an electronic version of the information sheet and the Mood Disorder Questionnaire (MDQ). If they scored in either the ‘low MDQ’ or the ‘high MDQ’ category they were invited for a first study visit.

During the first study visit, inclusion and exclusion criteria were checked. Participants were also screened for psychiatric disorders using the Structured Clinical Interview for DSM Disorders (SCID) (7). Participants completed several questionnaires, including Barratt Impulsiveness Scale (8), Sleep Condition Indicator (9), Maclean Screening Instrument (10), Affective Lability Scale (11), Affect Intensity Measure (12). Participants were set up with and instructed how to use devices to measure their activity (GeneActiv watch and FitBit) over the ten weeks study period. They were given an iPad mini and trained on four cognitive tasks: ‘wheel of fortune’ – risky decision making (presented here), ‘guess the gap’ – performance learning, ‘fractals’ – stimulus-outcome learning, ‘whack-a-t’ – implicit spatial learning.

Over a period of ten weeks, they were asked to complete these tasks five times a week and to wear the GeneActiv and FitBit devices as much as possible. They were also asked to complete clinical questionnaires (Quick Inventory of Depressive Symptomatology (13) , Altman self-rating mania scale (14), Generalized Anxiety Disorder-7 (15), EuroQol-5 [health-related quality of life] (16)) on the True Colours mood monitoring system (17) once a week. They were also asked to stay within the recommended daily alcohol intake levels throughout.

In the beginning of the ten-week period (weeks one or two) and in the end (weeks nine and ten), participants attended an MRI scan and a MEG scan. Due to MEG scanner downtime, only 24 participants received the MEG scan. During both MRI scans, resting state and structural data was obtained. At the first scan, additionally the ‘wheel of fortune’ was measured. At the second MRI scan, ‘fractals’ and ‘guess the gap’ was measured, as well as diffusion tensor imaging and fluid-attenuated inversion recovery.

**Participants diagnosed with bipolar disorder:**



Participants first took part in a screening visit in which inclusion criteria were checked and informed consent was taken. Using the SCID-I, a diagnosis check was done. In addition, demographic and clinical information was obtained, including duration of illness, previous use of psychotropic medicines, family history of mood disorders, presence of comorbid borderline personality disorder and attention deficit hyperactivity disorder and current suicidal ideation, concomitant medication and substance use and a physical examination. If blood samples have not been taken as part of routine monitoring, they were taken at this visit. Two sets of samples were taken, one was sent to the pathology lab for analysis and the other was retained as replacement for samples lost/damaged in transit and for storage for future research. Tests included urea and electrolytes, full blood count, fasting blood glucose, glycosylated haemoglobin (HbA1c), blood lipid profile, LFTs, T4, T3, TSH, thyroid antibodies, PTH, vitamin D, eGFR, Cystatin C and NGAL and inflammatory markers CRP and IL-6. A sample was taken to measure calcium level using the InSight™ Electrolyte Analyser located in the NIHR-CRF. Weight/BMI, pulse and blood pressure were also recorded, and an ECG was performed. Participants were given an iPad mini and trained on the same cognitive tasks as the healthy volunteers described above. They were also set up with the True Colours system to rate weekly mood and on Mood Zoom (18) to rate daily mood. Participants were also given activity monitors. They were also given saliva swabs.

Before being randomised to lithium or placebo, all participants completed two weeks of daily cognitive tasks, mood and activity measurements at home (though some participants completed up to 30 days due to logistic challenges). Then, they were randomised and performed six weeks of cognitive tasks, mood and activity measurements.

In the beginning of the six weeks period (week one or two), they completed an MRI and a MEG scan using the same scans as described for the healthy volunteers.

### **[1C] Lithium dosing information**

In the lithium group, participants were prescribed an initial dose of 400g/day, unless there was a clinical indication to start at a lower dose. During this phase, participants attended brief assessments at 4-days, 8-days and between 2 and 3 weeks post-randomisation to review lithium levels by a psychiatrist (if lithium level  $\leq 0.3$  mmol/L, dose increased to 800mg/day; if lithium level between 0.4 to 0.5 mmol/L, dose increased to 600mg/day; if lithium level 0.6 - 1.0mmol/L, continued current dose; if lithium level  $\geq 1.0$ mmol/L, decrease dose by 200mg/day or 400mg/day as found appropriate by psychiatrist), receive additional supplies of lithium/ placebo as needed and were asked about adverse events. Participants took part in one neuroimaging session in week 3 or 4. During the trial, participants were asked to complete the cognitive tasks daily.

### **[2] Computational modelling, additional information**

#### **[2A] Decision making model validation**

We validated our computational models using simulations (19,20). We simulated 400 participants with parameter values (mean and standard deviations) drawn from a uniform distribution in the 95% range of the parameters for real individual participants. For each participant, we simulated 47-50 sessions (uniform distribution). Parameters for single sessions were drawn from normal distributions of simulated participants' means, standard

deviations and linear effects of days. Simulated data was then fitted using same approaches as above. To speed up fitting of data, variational Bayesian approximation (21) was used unless control indices (pareto smoothed importance sampling,  $\hat{R} > 0.7$  (22)) suggested unsuccessful fitting even after increasing number of samples and decreasing tolerance, in which case sampling was used. When fitting the models, initially, 4 chains, with each 15,000 iterations were drawn and the target acceptance rate (`adapt_delta`, (23)) was set to 0.85. Whether models had been fit appropriately was checked using a criterion of  $\hat{R}$  (measure of mixing of chains)  $< 1.1$  and absence of divergent samples. If these were not fulfilled, number of iterations were increased by 50% and `adapt_delta` was increased towards 1 (by 50% of distance from 1). This was repeated until all models converged.

To validate the model, we then checked the correlations between true and fitted values for mean and standard deviation of parameters across individual subjects (table S1).

### **[2B] Bayesian models – additional information for standard settings**

Regression models were computed with the BRMS toolbox (24) which uses the Bayesian programming language Stan (25). The key advantages of the Bayesian approach are: priors can be defined to ease fitting, particularly when little data is available (as here only 20 trials per session); models can be hierarchical and account for individual differences in each parameter (i.e. taking into account data consistent of within and between subject measurements, e.g. several data points per person and several subjects); variability in measurements across people can be taken into account.

#### **Linear non-hierarchical regression**

All regression estimates (parameters) were given flat priors for all parameters and 10,000 iterations for each of four chains were drawn (target acceptance rate, `adapt_delta` = 0.9). Model fit was checked using criterion of  $\hat{R} < 1.1$  and the absence of divergent samples (23)

#### **Linear hierarchical regressions**

To ease fitting (26), all regression estimates were given weakly informative priors,  $\text{normal}(0,5)$ . 6,000 iterations for each of 4 chains were drawn (target acceptance rate, `adapt_delta` = 0.9). Model fit was checked as above for non-hierarchical models. Significance follows the standard definition of the Bayesian 95% Credible Interval not including zero. To compare individual groups, the same model was fitted with group as an unordered factor and posthoc tests were then done using the `emmeans` package (27) (again using 95% Credible Intervals to define significance). Results of regressions are illustrated as conditional effects, i.e. all other variables are set to their mean. We computed mean parameters for individual participants to relate to neural activity.

#### **Computational decision-making models – prior settings**

For each parameter weakly informative priors were specified for models for the longitudinal or the fMRI data for each session (longitudinal) or person (fMRI): inverse temperature ( $\beta$ ):  $\text{cauchy}(5,3)$ , weighting of the loss utility ( $\lambda$ ):  $\text{cauchy}(-1,1)$ , the impact of the previous trial's

win/loss on the weighting of the loss utility ( $\gamma$ ); group level standard deviations: inverse temperature ( $\beta$ ): cauchy(0,3), all other parameters: cauchy(0, 1).

When fitting the decision-making models, number of iterations and adapt\_delta were increased until fit indices suggested appropriate fit, as described above.

### **FMRI**

Computational models were fitted as for the longitudinal data, i.e. first separately for each individual participant before then comparing the computational model parameters across groups using non-hierarchical models (as one FMRI session per person).

### **[2C] Regressions relating mood, task outcomes and behaviour**

We used hierarchical regression models to test for group differences in the impact of task outcomes on mood:

Mean: Happiness (post minus pre)  $\sim 1 + \text{Task outcomes} * \text{group} + \text{Task outcomes} + \text{group} + \text{day} + \text{Age} + \text{Gender} + (1 + \text{day} + \text{outcome} | \text{ID})$

And error term:  $\text{sigma} \sim 1 + \text{group} + \text{age} + \text{gender} + (1 | \text{ID})$

Where outcome was either the total wins in the daily task, the total losses or the total wins minus losses. Group was coded as monotonic factor.

In addition to the happiness VAS that was measured before and after the task, we also measured mood using a more detailed questionnaire (PANAS-SF) before the task. We used this to replicate previous findings (18,28–30) of mood instability related to bipolar disorder (with hierarchical models):

Mean: PANAS  $\sim 1 + \text{day} + \text{group} + \text{age} + \text{gender} + (1 + \text{day} | \text{ID})$

Error term:  $\text{Sigma} \sim 1 + \text{group} + \text{age} + \text{gender} + (1 | \text{ID})$

Where PANAS was either the positive or the negative PANAS score.

### **[3] MRI scan**

#### **[3A] MRI acquisition sequences**

Scan protocols were similar across both sites and differences are highlighted. T1-weighted structural images were acquired with the settings TR=3 sec, TE=4.71 msec (4.65ms for second site [some bipolar patients]), TI (inversion time) = 1.1 sec, 1x1x1 mm voxel size, 256x176x224 mm grid, flip angle = 8°, phase-encoding direction = R-L, GRAPPA (Generalized autocalibrating partially parallel acquisition) = 2. Functional images were acquired using a Deichmann echo-planar imaging (EPI) sequence with TR=3 s, TE=30 ms, 3x3x3 mm voxel size, 87° flip angle, 30° slice angle and z-shimming to reduce signal distortions as well as dropout in medial orbitofrontal areas (31). A fieldmap with dual echo-time images (TE1 = 5.19 ms, TE2 = 7.65 ms, whole brain coverage, voxel size 3.5 × 3.5 × 3.5 mm) was obtained for each subject to allow for corrections in geometric distortions induced in the functional images.

#### **[3B] FMRI preprocessing**

We used FSL (32) version 6.00 for standard image preprocessing and analysis (suppl. Methods [4B]). We used FSL's BET (33) on the high-resolution structural MRI images and fieldmaps images to separate brain matter from nonbrain matter. We used the structural images to

register functional images in MNI space using nonlinear registration as implemented in FNIRT (34). Functional images were corrected for motion using FSL's MCFLIRT (35), corrected for geometric distortions using FSL's FUGUE (FMRIB's Utility for Geometrically Unwarping EPIs) and spatially smoothed with a Gaussian kernel of 5mm full-width half-maximum. Finally, images were then high-pass filtered with a 3 dB cutoff of 100s.

### [3C] fMRI analysis

The fMRI design was as follows (see figure S2 for design correlation matrix): We included four boxcar regressors capturing the different phases of each trial: the decision phase (aligned to the onset of the decision phase and lasting until participants could make a choice), the spinning phase (aligned to when the indicator on the chosen wheel of fortune started moving and lasting until it stopped), the outcome phase (the time the outcome was shown to participants and lasting until it disappeared from the screen) and the total score phase (aligned to when the screen with the total score was shown and lasting until it disappeared). Here the decision and the outcome phase are the main phases of interest, the others are included as control regressors. We also included parametric boxcar regressors aligned to same onsets as the phases described above, but with duration one second. All regressors were z-score normalized within each participant. In the decision phase, we included separate regressors for the reward and loss utilities (i.e. probability x magnitude) of the chosen minus the unchosen options, a regressor for last trial's outcome (win/loss, including the magnitude therefore, e.g. +10 or -20), as well as participants' log-transformed reaction time as a control regressor. In the outcome phase, we included a regressor indicating the current trial's outcome (win/loss, including the magnitude thereof). As control regressor we also included the total score phase with total scores as parametric value. All regressors were convolved with a double-gamma hemodynamic response function.

### References

1. Mars RB, Jbabdi S, Sallet J, O'Reilly JX, Croxson PL, Olivier E, *et al.* (2011): Diffusion-weighted imaging tractography-based parcellation of the human parietal cortex and comparison with human and macaque resting-state functional connectivity. *Journal of Neuroscience* 31: 4087–4100.
2. Neubert F-X, Mars RB, Sallet J, Rushworth MFS (2015): Connectivity reveals relationship of brain areas for reward-guided learning and decision making in human and monkey frontal cortex. *PNAS* 112: E2695–E2704.

3. Sallet J, Mars RB, Noonan MP, Neubert F-X, Jbabdi S, O'Reilly JX, *et al.* (2013): The Organization of Dorsal Frontal Cortex in Humans and Macaques. *J Neurosci* 33: 12255–12274.
4. Diedrichsen J, Balsters JH, Flavell J, Cussans E, Ramnani N (2009): A probabilistic MR atlas of the human cerebellum. *NeuroImage* 46: 39–46.
5. Neubert F-X, Mars RB, Thomas AG, Sallet J, Rushworth MF (2014): Comparison of human ventral frontal cortex areas for cognitive control and language with areas in monkey frontal cortex. *Neuron* 81: 700–713.
6. Nilsson ME, Suryawanshi S, Gassmann-Mayer C, Dubrava S, McSorley P, Jiang K (2013): Columbia–suicide severity rating scale scoring and data analysis guide. *CSSRS Scoring Version 2*: 1–13.
7. First MB (2014): Structured clinical interview for the DSM (SCID). *The encyclopedia of clinical psychology* 1–6.
8. Patton JH, Stanford MS, Barratt ES (1995): Factor structure of the Barratt impulsiveness scale. *Journal of clinical psychology* 51: 768–774.
9. Espie CA, Kyle SD, Hames P, Gardani M, Fleming L, Cape J (2014): The Sleep Condition Indicator: a clinical screening tool to evaluate insomnia disorder. *BMJ open* 4: e004183.
10. Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J (2003): A screening measure for BPD: The McLean screening instrument for borderline personality disorder (MSI-BPD). *Journal of personality disorders* 17: 568–573.
11. Oliver MN, Simons JS (2004): The affective lability scales: Development of a short-form measure. *Personality and individual differences* 37: 1279–1288.

12. LARSEN RJ (1984): *Theory and Measurement of Affect Intensity as an Individual Difference Characteristic (Temperament, Emotion, Arousal)*. University of Illinois at Urbana-Champaign.
13. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, *et al.* (2003): The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. *Biological psychiatry* 54: 573–583.
14. Altman EG, Hedeker D, Peterson JL, Davis JM (1997): The Altman self-rating mania scale. *Biological psychiatry* 42: 948–955.
15. Spitzer RL, Kroenke K, Williams JB, Löwe B (2006): A brief measure for assessing generalized anxiety disorder: the GAD-7. *Archives of internal medicine* 166: 1092–1097.
16. Group TE (1990): EuroQol-a new facility for the measurement of health-related quality of life. *Health policy* 16: 199–208.
17. Goodday SM, Atkinson L, Goodwin G, Saunders K, South M, Mackay C, *et al.* (2020): The True Colours Remote Symptom Monitoring System: A Decade of Evolution. *Journal of Medical Internet Research* 22: e15188.
18. Tsanas A, Saunders KEA, Bilderbeck AC, Palmius N, Osipov M, Clifford GD, *et al.* (2016): Daily longitudinal self-monitoring of mood variability in bipolar disorder and borderline personality disorder. *Journal of affective disorders* 205: 225–233.
19. Kolling N, Scholl J, Chekroud A, Trier HA, Rushworth MF (2018): Propection, perseverance, and insight in sequential behavior. *Neuron* 99: 1069–1082.
20. Scholl J, Trier HA, Rushworth MF, Kolling N (2022): The effect of apathy and compulsivity on planning and stopping in sequential decision-making. *PLoS biology* 20: e3001566.

21. Kucukelbir A, Ranganath R, Gelman A, Blei DM (2015): Automatic variational inference in Stan. *arXiv preprint arXiv:150603431*.
22. Yao Y, Vehtari A, Simpson D, Gelman A (2018): Yes, but did it work?: Evaluating variational inference. *International Conference on Machine Learning* 5581–5590.
23. Gelman A, Vehtari A, Simpson D, Margossian CC, Carpenter B, Yao Y, *et al.* (2020): Bayesian workflow. *arXiv preprint arXiv:201101808*.
24. Bürkner P-C (2017): brms: An R package for Bayesian multilevel models using Stan. *Journal of Statistical Software* 80: 1–28.
25. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, *et al.* (2017): Stan : A Probabilistic Programming Language. *Journal of Statistical Software* 76. <https://doi.org/10.18637/jss.v076.i01>
26. Michael Betancourt (2017): How the shape of a weakly informative prior affects inferences. Retrieved from [https://mc-stan.org/users/documentation/case-studies/weakly\\_informative\\_shapes.html](https://mc-stan.org/users/documentation/case-studies/weakly_informative_shapes.html)
27. Lenth RV (2021): *Emmeans: Estimated Marginal Means, Aka Least-Squares Means*. Retrieved from <https://CRAN.R-project.org/package=emmeans>
28. Bonsall MB, Wallace-Hadrill SMA, Geddes JR, Goodwin GM, Holmes EA (2012): Nonlinear time-series approaches in characterizing mood stability and mood instability in bipolar disorder. *Proceedings of the Royal Society B: Biological Sciences* 279: 916–924.
29. Holmes EA, Bonsall MB, Hales SA, Mitchell H, Renner F, Blackwell SE, *et al.* (2016): Applications of time-series analysis to mood fluctuations in bipolar disorder to promote treatment innovation: a case series [no. 1]. *Transl Psychiatry* 6: e720–e720.
30. Pulcu E, Saunders KEA, Harmer CJ, Harrison PJ, Goodwin GM, Geddes JR, Browning M (2022): Using a generative model of affect to characterize affective variability and its

response to treatment in bipolar disorder. *Proceedings of the National Academy of Sciences* 119: e2202983119.

31. Deichmann R, Gottfried JA, Hutton C, Turner R (2003): Optimized EPI for fMRI studies of the orbitofrontal cortex. *NeuroImage* 19: 430–441.
32. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, *et al.* (2004): Advances in functional and structural MR image analysis and implementation as FSL. *Neuroimage* 23: S208–S219.
33. Smith SM (2002): Fast robust automated brain extraction. *Human brain mapping* 17: 143–155.
34. Andersson JL, Jenkinson M, Smith S (2007): Non-linear registration aka Spatial normalisation FMRIB Technical Report TR07JA2. *FMRIB Analysis Group of the University of Oxford*.
35. Jenkinson M, Bannister P, Brady M, Smith S (2002): Improved optimization for the robust and accurate linear registration and motion correction of brain images. *Neuroimage* 17: 825–841.